CNBC’s Becky Quick to Moderate High-Level CEO Dialogue on the Future of Rare Disease Innovation at NORD’s 2026 Breakthrough Summit

WASHINGTON, D.C. and NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has announced that prominent business journalist and CNBC “Squawk Box” co-anchor Becky Quick will moderate a flagship executive leadership panel during its upcoming national conference. The high-profile discussion, titled “Next Decade of Rare Disease: A CEO Leadership Dialogue,” will feature the chief executive officers of BioMarin, Jazz Pharmaceuticals, and Otsuka alongside NORD Chief Executive Officer Pam Gavin.

The scheduled conversation forms a centerpiece of the 16th annual NORD® Rare Diseases & Orphan Products Breakthrough Summit®, a premier three-day event taking place from October 25 to 27, 2026, in Washington, D.C. The CEO panel itself is slated for 11 a.m. ET on Monday, October 26. Industry professionals, patient advocates, researchers, and healthcare leaders can access full agenda details and registration information by visiting NORDSummit.org.

This year’s leadership dialogue arrives at a critical juncture for the global rare disease community. Unprecedented scientific and technological breakthroughs are rapidly expanding the boundaries of what is possible in medical diagnosis and therapeutic intervention. However, industry stakeholders increasingly recognize that scientific discovery alone is insufficient to transform human health outcomes. Realizing the full potential of these innovations will require regulatory frameworks, forward-thinking public policies, sustained capital investment, modernized healthcare infrastructure, and efficient treatment delivery systems to evolve in tandem.

The upcoming panel is designed to examine the high-level decisions, corporate strategies, and cross-sector partnerships necessary to capitalize on this historical moment. Furthermore, the dialogue will directly address the complex challenge of scale—specifically, how the biopharmaceutical sector and advocacy ecosystem can successfully accelerate the translation of scientific milestones into approved, accessible treatments across a broader spectrum of rare conditions.

The distinguished panel brings together a powerful combination of global corporate perspectives and patient advocacy leadership. The biopharmaceutical CEOs participating in the dialogue represent multinational enterprises with diverse rare disease portfolios, robust clinical pipelines, and extensive operational experience in steering complex therapies through development, regulatory approval, and commercialization. Complementing their industry viewpoints, Pam Gavin will bring NORD’s independent, cross-disease patient and systems-level perspective. Her leadership ensures that the conversation bridges the gap between commercial and scientific ambitions and the diverse, pressing unmet needs experienced by individuals living with any of the more than 10,000 known rare diseases.

Becky Quick brings decades of distinguished experience covering global business, macroeconomic trends, and financial markets for CNBC, during which she has interviewed many of the world’s most influential corporate leaders. In addition to her professional expertise, Quick holds a profound personal connection to the rare disease community as a parent of a child living with a rare condition. Her unique vantage point will enable her to guide the executive panel through a nuanced exploration of how organizational leaders can maximize the impact of emerging science and scale individual therapeutic triumphs into widespread progress for patients worldwide.

CNBC’s Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD

“We are at an important moment for rare disease. Science is opening doors that would have been unimaginable even a decade ago, but discovery alone does not ensure those advances reach the people who need them,” said Pam Gavin, CEO of NORD, emphasizing the urgency of the dialogue. “Realizing that potential will require leadership across the rare disease ecosystem to remove barriers, keep pace with innovation and translate progress into better outcomes for more people across more rare diseases. That is why this conversation—and the Breakthrough Summit—matter right now.”

Now in its sixteenth year, the NORD Rare Disease & Orphan Products Breakthrough Summit has established itself as an essential annual gathering, drawing more than 900 key decision-makers from across the entire rare disease ecosystem. Attendees typically include representatives from biotechnology and pharmaceutical companies, patient advocacy groups, academic research institutions, federal regulatory agencies, and healthcare payers.

The comprehensive programming of the Breakthrough Summit spans a wide array of critical topics shaping the future of rare disease research, regulatory policy, clinical care, and patient access. Sessions are carefully curated to address federal health priorities, emerging therapeutic modalities such as gene and cell therapies, investment strategies, innovative patient partnerships, and the systemic improvements required to streamline the journey of a therapy from laboratory discovery to the patient bedside.

Adding to the national significance of the 2026 event, the Breakthrough Summit will feature prominent keynote addresses and interactive discussions with senior federal health leaders. Among the confirmed high-ranking government officials participating in the summit are Kyle Diamantas, J.D., Acting Commissioner of the U.S. Food and Drug Administration (FDA), and Jay Bhattacharya, M.D., Ph.D., Director of the National Institutes of Health (NIH). Their involvement underscores the vital public-private dialogue that characterizes the annual gathering.

The overarching ethos of the NORD Breakthrough Summit remains rooted in cross-sector collaboration, operating on the premise that the intricate challenges facing the rare disease community are too vast for any single organization, corporation, or government agency to solve in isolation. By convening diverse stakeholders under one roof, the summit aims to foster actionable solutions that accelerate patient progress.

Founded in 1983, the National Organization for Rare Disorders (NORD) serves as an independent, nonpartisan, 501(c)(3) nonprofit organization dedicated to improving the health and lives of the more than 30 million Americans who live with rare diseases. Working in active partnership with over 350 disease-specific member organizations, NORD acts as a unified voice for the community, driving advancements in biomedical research, patient support services, and public health policy.

Reynand Wu

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya